Round 2 of Monkeypox Stocks

Here's a fresh list of mpox stocks that are already seeing... [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy Round 2 of Monkeypox Stocks Jason Williams | Aug 27, 2024 Dear Reader, Since I last wrote to you with a list of potential investments that could benefit from the recent monkeypox outbreak, that outbreak has gotten even worse. And I’ve learned that the preferred term for what I called monkeypox stocks is actually mpox stocks. So, since I made a mistake and called them monkeypox stocks… and since the outbreak has now spread outside of Africa… I’ve got a fresh list of mpox stocks that are already seeing some BIG investor interest. Before we get into our updated list of [mpox stocks](, let’s cover what we know about the virus. It’s the more severe version. We know that. And it’s part of the same family that causes smallpox. That might sound pretty bad, but it means that this virus responds to some of the vaccines we’ve already developed for smallpox. That’s why Bavarian Nordic (OTC: BVNRY) is doing so well as one of my original mpox stocks. Its smallpox vaccine is the preferred preventative. It’s estimated that about 10 million vaccine doses are needed to address the outbreak in Africa. That’s a lot of vaccine. And that’s just for Africa. But will Bavarian Nordic be the only vaccine maker? Or are there some others that could turn into profitable mpox stocks? Let’s take a look…  [Read the full article here.]( [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).